RxDoctor Payments Data

Neal Honickman, MD

Ophthalmology · Brandon, FLNPI 1912902487

Payments from drug & device makers

$1,476in general payments, 2019–2025

Across 65 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ANI Pharmaceuticals, Inc.$414
  • AbbVie$282
  • Dompe US, Inc.$173
  • Genentech USA, Inc.$110
  • Amgen$104
  • Novartis$86
  • plus $307 from 11 others

What the payments were for

  • Food & beverage$1,45699%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,476 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$1,516,897
Medicare patients
753
Services billed
16,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept178$576,562
IzervayAvacincaptad Pegol Sodium/Pf82$247,033
VabysmoFaricimab-Svoa29$121,592
RestasisCyclosporine29$25,279
LumiganBimatoprost69$23,752
CombiganBrimonidine Tartrate/Timolol38$15,016
VyzultaLatanoprostene Bunod28$11,241
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol59$8,823
Brimonidine Tartrate77$8,165
SimbrinzaBrinzolamide/Brimonidine Tart31$6,241
Latanoprost378$3,582
Prednisolone Acetate88$2,382
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$883
Timolol Maleate88$806
ErythromycinErythromycin Base31$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncIzervay$64$247,03382 claims
Genentech USA, Inc.Vabysmo$110$121,59229 claims
AbbVieRestasis, Lumigan, Combigan$282$64,048136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →